But it’s up to your specific plan to decide whether it covers a certain insulin drug, such as Basaglar. Basaglar is a long-acting insulin medication delivered through insulin pens called KwikPens.
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
The Basaglar NDA was filed through the FDA's 505(b)(2) regulatory pathway, which allows the agency to consider the efficacy and safety of the existing insulin glargine product.